1-9 of 9
Tod Smeal
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B108: Antitumor efficacy of EGFR antibody necitumumab and dual PI3K/mTOR inhibitor (LY3023414) in preclinical tumor models

Maxine A. Melchior, Xuemei Guo, Gregory P. Donoho, Philip W. Iversen, Thompson N. Doman, Manisha Brahmachary, Xueqian Gong, Gerald E. Hall, Jason R. Manro, Yung-mae M. Yao, Sean Buchanan, Tod Smeal, Michael D. Kalos, Ruslan D. Novosiadly
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): B108.
https://doi.org/10.1158/1535-7163.TARG-17-B108
Published: 01 January 2018
View article titled, Abstract B108: Antitumor efficacy of EGFR antibody necitumumab and dual PI3K/mTOR inhibitor (LY3023414) in preclinical tumor models
Journal Articles

Abstract PR10: Is CNS availability for oncology a no-brainer? Discovery of PF-06463922, a novel small molecule inhibitor of ALK/ROS1 with preclinical brain availability and broad spectrum potency against ALK-resistant mutations.

Ted W. Johnson, Simon Bailey, Benjamin J. Burke, Michael R. Collins, J. Jean Cui, Judy Deal, Ya-Li Deng, Martin P. Edwards, Mingying He, Jacqui Hoffman, Robert L. Hoffman, Qinhua Huang, Robert S. Kania, Phuong Le, Michele McTigue, Cynthia L. Palmer, Paul F. Richardson, Neal W. Sach, Graham L. Smith, Lars Engstrom, Wenyue Hu, Hieu Lam, Justine L. Lam, Tod Smeal, Helen Y. Zou
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): PR10.
https://doi.org/10.1158/1535-7163.TARG-13-PR10
Published: 01 November 2013
View article titled, Abstract PR10: Is CNS availability for oncology a no-brainer? Discovery of PF-06463922, a novel small molecule inhibitor of ALK/ROS1 with preclinical brain availability and broad spectrum potency against ALK-resistant mutations.
Journal Articles

Abstract A277: PF-06463922, a novel ROS1/ALK inhibitor, demonstrates sub-nanomolar potency against oncogenic ROS1 fusions and capable of blocking the resistant ROS1G2032R mutant in preclinical tumor models.

Helen Y. Zou, Lars R. Engstrom, Qiuhua Li, Melissa West Lu, Ruth Wei Tang, Hui Wang, Konstantinos Tsaparikos, Sergei Timofeevski, Justine Lam, Shinji Yamazaki, Wenyue Hu, Hovhannes Gukasyan, Nathan Lee, Ted W. Johnson, Valeria Fantin, Tod Smeal
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A277.
https://doi.org/10.1158/1535-7163.TARG-13-A277
Published: 01 November 2013
View article titled, Abstract A277: PF-06463922, a novel ROS1/ALK inhibitor, demonstrates sub-nanomolar potency against oncogenic ROS1 fusions and capable of blocking the resistant ROS1<sup>G2032R</sup> mutant in preclinical tumor models.
Journal Articles

Abstract C253: PF-06463922, a novel brain-penetrating small molecule inhibitor of ALK/ROS1 with potent activity against a broad spectrum of ALK resistant mutations in preclinical models in vitro and in vivo.

Helen Y. Zou, Lars R. Engstrom, Qiuhua Li, Melissa West Lu, Ruth Wei Tang, Hui Wang, Konstantinos Tsaparikos, Jinwei Wang, Sergei Timofeevski, Dac M. Dinh, Hieu Lam, Justine Lam, Shinji Yamazaki, Wenyue Hu, Timothy Affolter, Patrick B. Lappin, Hovhannes Gukasyan, Nathan Lee, Jennifer M. Tursi, Ted W. Johnson, Valeria Fantin, Tod Smeal
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C253.
https://doi.org/10.1158/1535-7163.TARG-13-C253
Published: 01 November 2013
View article titled, Abstract C253: PF-06463922, a novel brain-penetrating small molecule inhibitor of ALK/ROS1 with potent activity against a broad spectrum of ALK resistant mutations in preclinical models in vitro and in vivo.
Journal Articles

Epithelial Tissue Hyperplasia Induced by the RAF Inhibitor PF-04880594 Is Attenuated by a Clinically Well-Tolerated Dose of the MEK Inhibitor PD-0325901

Vince R. Torti, Donald Wojciechowicz, Wenyue Hu, Annette John-Baptiste, Winston Evering, Gabriel Troche, Lisa D. Marroquin, Tod Smeal, Shinji Yamazaki, Cynthia L. Palmer, Leigh Ann Burns-Naas, Shubha Bagrodia
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (10): 2274–2283.
https://doi.org/10.1158/1535-7163.MCT-11-0984
Published: 09 October 2012
View article titled, Epithelial Tissue Hyperplasia Induced by the RAF Inhibitor PF-04880594 Is Attenuated by a Clinically Well-Tolerated Dose of the MEK Inhibitor PD-0325901
Open the PDF for Epithelial Tissue Hyperplasia Induced by the RAF Inhibitor PF-04880594 Is Attenuated by a Clinically Well-Tolerated Dose of the MEK Inhibitor PD-0325901 in another window
Includes: Supplementary data
Journal Articles

Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor

Helen Y. Zou, Qiuhua Li, Joseph H. Lee, Maria E. Arango, Kristina Burgess, Ming Qiu, Lars D. Engstrom, Shinji Yamazaki, Max Parker, Sergei Timofeevski, Jingrong Jean Cui, Michele McTigue, Gerrit Los, Steven L. Bender, Tod Smeal, James G. Christensen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (4): 1036–1047.
https://doi.org/10.1158/1535-7163.MCT-11-0839
Published: 08 April 2012
View article titled, Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor
Open the PDF for Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor in another window
Includes: Supplementary data
Journal Articles

Evaluation of Selective γ-Secretase Inhibitor PF-03084014 for Its Antitumor Efficacy and Gastrointestinal Safety to Guide Optimal Clinical Trial Design

Ping Wei, Marlena Walls, Ming Qiu, Richard Ding, Robert H. Denlinger, Anthony Wong, Kosta Tsaparikos, Jitesh P. Jani, Natilie Hosea, Michelle Sands, Sophia Randolph, Tod Smeal
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (6): 1618–1628.
https://doi.org/10.1158/1535-7163.MCT-10-0034
Published: 09 June 2010
View article titled, Evaluation of Selective γ-Secretase Inhibitor PF-03084014 for Its Antitumor Efficacy and Gastrointestinal Safety to Guide Optimal Clinical Trial Design
Open the PDF for Evaluation of Selective γ-Secretase Inhibitor PF-03084014 for Its Antitumor Efficacy and Gastrointestinal Safety to Guide Optimal Clinical Trial Design in another window
Includes: Supplementary data
Journal Articles

Abstract B169: Characterization of in vitro activity and predictive biomarkers of the novel p21‐activated kinase 4 (PAK4) inhibitor, PF‐3758309, in colorectal cancer cell lines

Gillian N. Kulikowski, Todd M. Pitts, Aik Choon Tan, John J. Tentler, Blair C. Britt, Byron W. Britt, Brion W. Murray, William Carley, Tod Smeal, Chuangxing Guo, S. Gail Eckhardt
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B169.
https://doi.org/10.1158/1535-7163.TARG-09-B169
Published: 10 December 2009
View article titled, Abstract B169: Characterization of <em>in vitro</em> activity and predictive biomarkers of the novel p21‐activated kinase 4 (PAK4) inhibitor, PF‐3758309, in colorectal cancer cell lines
Journal Articles

Abstract PR-2: Discovery of p21‐activated kinase inhibitor PF‐03758309

Chuangxing Guo, Junhu Zhang, Indrawan McAlpine, Catherine Johnson, Joseph Marakovits, Liming Dong, Susan Kephart, Anle Yang, Jayashree Tikhe, Haitao Li, Lisa Guo, Djamal Bouzida, Ya‐Li Deng, Dan Knighton, Joseph Piraino, Joseph Lee, Tod Smeal, Jamie Christensen, Eugenia Kraynov, Cho‐Ming Loi, Hasam Younis, Eleanor Dagostino, Brion W. Murray
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): PR-2.
https://doi.org/10.1158/1535-7163.TARG-09-PR-2
Published: 10 December 2009
View article titled, Abstract PR-2: Discovery of p21‐activated kinase inhibitor PF‐03758309